Dr. Stephanie Pautke speaks on “Lizenzierung und Kartellrecht unter besonderer Berücksichtigung der GVO Technologietransfer”
Business Breakfast, 20 November 2025, Frankfurt
Joint Business Breakfast with Dr. Christian Bitsch (BLUEDEX Labour Law)
Dr. Dominique Wagener speaks on “Kartellrechtliche Grenzen der Entgeltfindung: Was Unternehmen beachten müssen“
2nd Annual EU Competition Private Enforcement Forum 2025, 4 November 2025, Amsterdam
Dr. Dominique Wagener speaks on “Exploring Abuse of Dominance and DMA Claims”
VVP Herbst–Fachtagung 2025, 23 – 24 October 2025, Erfurt
Dr. Stephanie Pautke speaks on “Spielregeln im Wandel – Wettbewerbs- und Kartellrecht auf den Punkt”
Salzburg Global’s 2025 Corporate Governance Forum, 28 – 30 October 2025, Salzburg
Dr. Johanna Kübler speaks on “Defending Firms against Antitrust & Competition Laws”
AIJA – 12th Antitrust Annual Conference, 9 – 11 October 2025, Amsterdam
Franziska Lange-Schlüter speaks on “Shedding Light on Illumina: Navigating Uncertain Times for Below Threshold Transactions”
Geradin Partners’ Competition Law & Policy Conference, 22 – 23 September 2025, Antwerp
Dr. Dominique Wagener speaks on “Evolving Frontiers of Article 101 Enforcement”
Competition Law Summer School 2025, 8 – 12 September 2025, University of Cambridge
Dr. Stephanie Pautke speaks on “Vertikal Agreements: Key Principles & Practical Concerns”
The Teva Copaxone Decision: Drawing the Line Between Pharma, IP Rights and Antitrust Law
A focused look at how the European Commission’s EUR 462.6 million Teva decision reshapes the concept of competition on the merits in pharma antitrust enforcement
Public Signaling and the Use of AI by the EU Commission to Detect Infringements
The Michelin decision of EU General Court highlights the antitrust concerns related to public communications by companies and sheds some light on the Commission’s use of market surveillance tools to detect potentially anti-competitive price signaling